雷公藤红素纳米颗粒靶向治疗心肌重构

Pathological myocardial remodelling remains one of the leading causes of death worldwide and has become a serious threat to human health. Chemotherapeutic agents are widely used in the treatment of cardiac diseases, but the systemic toxicity and inefficient cardiac targeting of chemotherapeutic agents have created an urgent need for the development of effective cardiac-targeted therapies. Celatrol has been shown to be useful in the treatment of myocardial remodelling. However, its poor water solubility and biocompatibility limit clinical applications. In order to overcome these difficulties a tretinoin nanoparticle (CaP@F127-CTP/mTAT@Cel,CFCMC) with cardiac targeting and cell penetration capabilities was developed. Characterisation results showed that CFCMC was successfully synthesised, and electron microscopy images analysed its average particle size is about 109.35 nm. Cardiac ex vivo imaging experiments and in vivo efficacy tests showed that CFCMC can be effectively delivered to the heart via the lungs, thereby exerting therapeutic effects against cardiac hypertrophy and cardiac fibrosis.